NCT00706628 - A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2008

Conditions

Prostatic Neoplasms

Interventions

DRUG

BIBF 1120

DRUG

BIBW 2992

DRUG

Sequential BIBF 1120 + BIBW 2992

Trial Locations (9)

1239.3.4402 Boehringer Ingelheim Investigational Site, Belfast

1239.3.4406 Boehringer Ingelheim Investigational Site, Bournemouth

1239.3.4408 Boehringer Ingelheim Investigational Site, Brighton

1239.3.4409 Boehringer Ingelheim Investigational Site, Cheltenham

1239.3.4405 Boehringer Ingelheim Investigational Site, Glasgow

1239.3.4403 Boehringer Ingelheim Investigational Site, Newcastle upon Tyne

1239.3.4411 Boehringer Ingelheim Investigational Site, Southampton

1239.3.4401 Boehringer Ingelheim Investigational Site, Sutton

1239.3.4410 Boehringer Ingelheim Investigational Site, Truro